DLL4

CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 8, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Vascular endothelial growth factor A, Therapy, Compass, Hillhouse Capital Group, Doctor of Philosophy, OTC, Safety, Cancer, Neurodegeneration, Population, SEC, AACR, ECOG, Stomach, ABL, Rest, Bevacizumab, ORR, Cholangiocarcinoma, Conference, KOSDAQ, Samsung Medical Center, Lists of diseases, Eli Lilly and Company, Abstract, Clinical trial, Multimedia, Partial, Immune system, Hypertension, CNS, Colorectal cancer, Tumor microenvironment, DLL4, DCR, Neoplasm, RECIST, Traffic barrier, BBB, CMO, Industry, Pulmonary hypertension, CDH, CEO, Patient, Pharmaceutical industry, Vaccine, CTX-009, Compass Therapeutics, ABL Bio, Elpiscience BioPharma, CTX-009, COMPASS THERAPEUTICS, ABL BIO, ELPISCIENCE BIOPHARMA

Among those, 7 patients reported Grade 3 hypertension and the rest had Grade 1 or Grade 2 (16%).

Key Points: 
  • Among those, 7 patients reported Grade 3 hypertension and the rest had Grade 1 or Grade 2 (16%).
  • Only 4 mild cases of pulmonary hypertension were reported that were all reversible, and CTX-009 demonstrated significant clinical activity as a stand-alone therapy.
  • This is a significant clinical result because current approved anti-angiogenic drugs have little efficacy as a monotherapy.
  • Elpiscience endeavors to advance at least one world-class molecule into the clinic each year, providing clinical benefits to cancer patients worldwide.

Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Friday, October 1, 2021
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Biotechnology, CNS, Therapy, Neurodegeneration, Neoplasm, Vascular endothelial growth factor A, OTC, Conference, Multimedia, Compass, AACR, Traffic barrier, Cholangiocarcinoma, Immune system, KOSDAQ, Industry, ABL, Safety, DLL4, Partial, BBB, Tumor microenvironment, SEC, Lists of diseases, Pharmaceutical industry, Vaccine, CTX-009, Compass Therapeutics, ABL Bio, CTX-009, COMPASS THERAPEUTICS, ABL BIO

Pre-clinical and early clinical data of CTX-009 suggests that blockade of both pathways provides robust anti-tumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic and non-small cell lung cancer.

Key Points: 
  • Pre-clinical and early clinical data of CTX-009 suggests that blockade of both pathways provides robust anti-tumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic and non-small cell lung cancer.
  • Partial responses to CTX-009 as a monotherapy have been observed in heavily pre-treated cancer patients, who were resistant to currently approved anti-VEGF therapies.
  • Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases.
  • ABL Bio, Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases.